Bicara director awarded 19,475 stock options

Bicara Therapeutics Inc. director Robertson Scott M. received a grant of stock options on Common Stock.

Accepted by SEC EDGAR 06/10/2026 - 04:33 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Bicara Therapeutics Inc. director Robertson Scott M. received a grant of stock options on Common Stock. The award covers 19,475 stock options with an exercise price of $20.56 per share, expiring on June 9, 2036.

The options vest upon the earlier of June 9, 2027 or the date of the next Annual Meeting of Stockholders, subject to his continued service on that vesting date. Following this grant, he holds 19,475 stock options directly.

Insider Trade Summary

Grant/Award: 19,475 shares

Grant/Award 1 txn

Insider Robertson Scott M.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	19,475	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 19,475 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this stock option vest upon the earlier of (i) June 9, 2027 or (ii) the date of the next Annual Meeting of Stockholders of Bicara Therapeutics Inc., subject to the Reporting Person's continued service on such vesting date.

Key Figures

Stock options granted: 19,475 options Exercise price: $20.56 per share Expiration date: June 9, 2036 +3 more

6 metrics

Stock options granted 19,475 options Grant to director on June 9, 2026

Exercise price $20.56 per share Stock option strike price

Expiration date June 9, 2036 Option term end

Underlying shares 19,475 shares Common Stock underlying the options

Post-transaction options held 19,475 options Total derivative holdings after grant

Vesting date trigger June 9, 2027 Earlier of this date or next Annual Meeting

Key Terms

Stock Option (Right to Buy), Common Stock, Annual Meeting of Stockholders, vest

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Annual Meeting of Stockholders financial

"the date of the next Annual Meeting of Stockholders of Bicara Therapeutics Inc."

vest financial

"The shares underlying this stock option vest upon the earlier of (i) June 9, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Bicara Therapeutics (BCAX) director Robertson Scott M. report on this Form 4?

He reported a grant of 19,475 stock options on Bicara Therapeutics Common Stock. These options were awarded at an exercise price of $20.56 per share, with the entire position shown as directly held after the transaction.

What are the key terms of the Bicara Therapeutics (BCAX) stock options granted?

The grant covers 19,475 stock options with an exercise price of $20.56 per share. The options expire on June 9, 2036 and relate to an equivalent number of shares of Bicara Therapeutics Common Stock as the underlying security.

When do the newly granted Bicara Therapeutics (BCAX) options vest?

The options vest upon the earlier of June 9, 2027 or the date of the next Annual Meeting of Stockholders. Vesting is conditioned on the director’s continued service with Bicara Therapeutics through that applicable vesting date.

How many Bicara Therapeutics (BCAX) options does the director hold after this Form 4 transaction?

After the reported grant, the director holds 19,475 stock options directly. This matches the full amount of the current award, and the filing does not show any other derivative positions remaining beyond this specific option grant.

Is the Bicara Therapeutics (BCAX) Form 4 transaction a market purchase or sale?

No, the filing reports a grant or award acquisition of stock options, coded as an “A” transaction. It reflects a compensation-related award rather than an open-market buy or sell of Bicara Therapeutics Common Stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Robertson Scott M.

(Last) (First) (Middle)

BICARA THERAPEUTICS INC.

116 HUNTINGTON AVENUE, SUITE 703

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bicara Therapeutics Inc. [ BCAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$20.56	06/09/2026		A		19,475		(1)	06/09/2036	Common Stock	19,475	$0	19,475	D

Explanation of Responses:

1. The shares underlying this stock option vest upon the earlier of (i) June 9, 2027 or (ii) the date of the next Annual Meeting of Stockholders of Bicara Therapeutics Inc., subject to the Reporting Person's continued service on such vesting date.

Remarks:

	/s/ Ryan Cohlhepp, Attorney-in-Fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)